aTyr Pharma, Inc. (LIFE) Financial Statements (2024 and earlier)

Company Profile

Business Address 10240 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments108,581114,38566,14677,37488,55498,666
Cash and cash equivalents12,31320,6909,98118,3598,4848,324
Short-term investments96,26893,69556,16559,01580,07090,342
Receivables1,2871,62511,775873426426
Prepaid expense4,5633,4372,9506,3864,3754,025
Total current assets:114,431119,44780,87184,63393,355103,117
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization1,8941,9481,248768368 
Operating lease, right-of-use asset7,1196,9427,2506,9718271,050
Property, plant and equipment5,8125,1673,0591,275558433
Restricted cash and investments3,4193,1903,1652,239733 
Other noncurrent assets72144193169175176
Total noncurrent assets:18,31617,39114,91511,4222,6611,659
TOTAL ASSETS:132,747136,83895,78696,05596,016104,776
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,30412,85312,96810,3988,2845,257
Accounts payable5163,9653,1063,1291,6741,563
Accrued liabilities10,7888,8889,8627,2696,6103,694
Debt44342026415870 
Other undisclosed current liabilities6213816306579061,012
Total current liabilities:12,36813,65413,86211,2139,2606,269
Noncurrent Liabilities
Long-term debt and lease obligation1,5251,5701,0077,836298133
Finance lease, liability1,5251,5701,007618298 
Liabilities, other than long-term debt12,80211,9169,633   
Operating lease, liability12,80211,9169,6337,218 133
Other undisclosed noncurrent liabilities    (7,218) (133)
Total noncurrent liabilities:14,32713,48610,6407,836298133
Total liabilities:26,69527,14024,50219,0499,5586,402
Equity
Equity, attributable to parent106,237109,87971,46477,18486,63598,550
Common stock575329292828
Additional paid in capital548,436539,659489,502487,937484,286483,730
Accumulated other comprehensive loss(333)(248)(433)(669)(810)(759)
Accumulated deficit(441,923)(429,585)(417,634)(410,113)(396,869)(384,449)
Equity, attributable to noncontrolling interest(185)(181)(180)(178)(177)(176)
Total equity:106,052109,69871,28477,00686,45898,374
TOTAL LIABILITIES AND EQUITY:132,747136,83895,78696,05596,016104,776

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues  10,386   
Gross profit:      
Operating expenses(13,558)(12,787)(18,336)(13,492)(12,584)(12,378)
Other undisclosed operating income   10,386   
Operating loss:(13,558)(12,787)(7,950)(13,492)(12,584)(12,378)
Nonoperating income1,216835427247163224
Loss from continuing operations before equity method investments, income taxes:(12,342)(11,952)(7,523)(13,245)(12,421)(12,154)
Other undisclosed income from continuing operations before income taxes   3   
Loss from continuing operations:(12,342)(11,952)(7,520)(13,245)(12,421)(12,154)
Loss before gain (loss) on sale of properties:(13,245)(12,421)(12,154)
Other undisclosed net loss   (3)   
Net loss:(12,342)(11,952)(7,523)(13,245)(12,421)(12,154)
Net income attributable to noncontrolling interest412111
Net loss available to common stockholders, diluted:(12,338)(11,951)(7,521)(13,244)(12,420)(12,153)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(12,342)(11,952)(7,523)(13,245)(12,421)(12,154)
Other undisclosed comprehensive income (loss)(85)185236141(51)(496)
Comprehensive loss:(12,427)(11,767)(7,287)(13,104)(12,472)(12,650)
Comprehensive income, net of tax, attributable to noncontrolling interest412111
Comprehensive loss, net of tax, attributable to parent:(12,423)(11,766)(7,285)(13,103)(12,471)(12,649)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: